Profil
Robert Shoemaker is currently the Senior Vice President-Research at Erasca, Inc. He previously worked as the Bioinformatics Director at Ignyta Operating, Inc. and as the Director-Bioinformatics Department at Ignyta, Inc. He also worked as a Scientist at Illumina, Inc. from 2011 to 2012.
Dr. Shoemaker obtained his undergraduate, graduate, and doctorate degrees from the University of California San Diego.
Aktive Positionen von Robert Shoemaker
| Unternehmen | Position | Beginn |
|---|---|---|
| ERASCA, INC. | Technik-/Wissenschafts-/F&E-Leiter | 18.01.2022 |
Ehemalige bekannte Positionen von Robert Shoemaker
| Unternehmen | Position | Ende |
|---|---|---|
| ILLUMINA, INC. | Corporate Officer/Principal | 01.01.2012 |
| IGNYTA INC | Corporate Officer/Principal | - |
Ignyta Operating, Inc.
Ignyta Operating, Inc. Pharmaceuticals: MajorHealth Technology Develops molecular diagnostics for cancer and immunology | Corporate Officer/Principal | - |
Ausbildung von Robert Shoemaker
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 5 |
|---|---|
Illumina, Inc.
Illumina, Inc. Medical SpecialtiesHealth Technology Operates as a biotechnology company that develops laboratory instruments | Health Technology |
Ignyta Operating, Inc.
Ignyta Operating, Inc. Pharmaceuticals: MajorHealth Technology Develops molecular diagnostics for cancer and immunology | Health Technology |
University of California San Diego
University of California San Diego Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Ignyta, Inc.
Ignyta, Inc. BiotechnologyHealth Technology Operates as a medicine biotechnology company which provides new drugs services for cancer patients | Health Technology |
Erasca, Inc.
Erasca, Inc. Pharmaceuticals: MajorHealth Technology Develops, discovers and commercializes therapies for RAS/MAPK pathway-driven cancers | Health Technology |
















